Login to Your Account



Other News To Note


Wednesday, April 25, 2012

• Ikaria Inc., of Hampton, N.J., gained approval in Australia for Lucassin (terlipressin) in the treatment of hepatorenal syndrome (HRS) Type 1, a type of kidney failure, in patients with advanced liver cirrhosis who are being considered for a kidney transplant.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription